01. Mesothelioma Care
Mesothelioma Care at UF Health Cancer Center
The Rod Taylor Thoracic Care Center at Orlando Health UF Health Cancer Center is comprised of board-certified surgeons, medical and radiation oncologists, pathologists, radiologists, nurses, therapists and counselors.
The Rod Taylor Thoracic Care Center provides exceptional care from specifically trained thoracic surgeons who focus on care for patients with lung, esophageal and other cancers malignancies in the chest including, mesothelioma. The devoted, multidisciplinary healthcare team works together to evaluate and determine the most effective means of treatment for each patient.
Malignant pleural mesothelioma occurs as a rare, malignant tumor originating from mesothelial cells surrounding the lungs. The thoracic surgeons at the Rod Taylor Thoracic Care Center are specifically trained to perform advanced surgery of thoracic tumors and use the most minimally invasive techniques for diagnosing, staging and treating various thoracic cancers.
The center was a pioneer in Central Florida for using the minimally invasive lung surgery procedure, video-assisted thoracic surgery (VATS), and the robotic thoracic surgery known as the Da Vinci Surgical System. They were also the first hospital to perform routine CT screenings that detect lung cancers that are rarely presented on an X-ray.
UF Health Cancer Center Specializations
- Integrative medicine
- LINX device
- Lung cancer screenings
- MRIdian treatment
- Radiation therapy
- Robotic thoracic surgery
- Thoracic cancer clinical trials
UF Health Cancer Center Accreditations
- American College of Surgeons (ACoS) Commission on Cancer Accreditation
- Florida Cancer Center of Excellence Award
- Lung Cancer Alliance Screening Center of Excellence
- Medical Oncology Certification
- Radiation Oncology Accreditation
04. Mesothelioma Clinical Trials
Mesothelioma Clinical Trials at UF Health Cancer Center
The following clinical trials are in progress or actively recruiting participants at UF Health Cancer Center:
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Conditions: Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Neoplasms
Last Updated: June 5, 2020
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Last Updated: February 19, 2020